Lv1
50 积分 2024-10-24 加入
Contrasting approaches for addressing non-adherence in randomized controlled trials: An illustration from the REFLUX trial
3个月前
已完结
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
4个月前
已完结
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
4个月前
已完结
皖公网安备34019202002308
